semaglutide and aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Semaglutide Treatment Experts at Minneapolis
Description
In our April issue of , Chris Aiken and David Liebers take a hard look at where these drugs really fit ( Highlights: , : GLP-1s can reverse antipsychotic weight gainsomething metformin rarely achieves once weight is established
Can creatine be the missing link in weight loss with GLP-1 drugs
In order to reveal the pathogenic mechanism of digestive diseases, it is necessary to establish a completer and more physiological organoid model
Learn what Phase 3 TRIUMPH trials confirm, what grey-market pens are, and what to expect at launch.
Discover the comprehensive guide to methylene blue, a versatile compound known for its antioxidant properties and potential cognitive benefits
